Skip to main content

Table 3 Whole Blood Clinical Chemistry Markers

From: Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement 6-OXO (androst-4-ene-3,6,17-trione) on serum hormone profiles and clinical safety markers in resistance-trained, eugonadal males

 

300 mg

600 mg

Week

0

1

3

8

11

0

1

3

8

11

WBC (K/μL)

5.3 ± 1.6

5.0 ± 1.1

5.3 ± 1.7

5.2 ± 2.0

4.5 ± 1.5

5.5 ± .96

4.6 ± .91

5.0 ± 1.0

4.9 ± .67

5.1 ± .84

RBC (M/μL)

5.0 ± .51

5.0 ± .50

4.6 ± .84

5.0 ± .37

4.9 ± .46

5.2 ± .37

5.1 ± .33

5.2 ± .24

4.9 ± 1.2

5.3 ± .30

Hemoglobin (g/dL)

15 ± 1.1

15 ± 1.1

15 ± 1.2

15 ± .59

15 ± 1.0

15 ± .95

15 ± .93

15 ± .63

15 ± .66

15 ± .78

Hematocrit (%)

44 ± 3.5

44 ± 3.7

44 ± 3.6

45 ± 2.4

43 ± 3.3

46 ± 3.0*

44 ± 2.3*

45 ± 1.9*

46 ± 2.1*

46 ± 2.7*

MCV (fL)

88 ± 2.8

88 ± 2.8

88 ± 2.4

89 ± 2.4

89 ± 2.9

87 ± 2.7

86 ± 2.8

87 ± 2.6

87 ± 2.3

87 ± 2.5

MCH (pg)

30 ± 1.2

30 ± 1.3

30 ± 1.0

30 ± 1.3

30 ± 1.0

29 ± 1.0

29 ± .95

29 ± .98

29 ± 1.1

29 ± .78

MCHC (g/dL)

34 ± .69

34 ± .76

34 ± .64

33 ± .78

34 ± .81

33 ± .60

34 ± .85

33 ± .56

33 ± .61

34 ± .60

Neutrophils

2.9 ± 1.0

2.5 ± .43

2.9 ± 1.1

2.8 ± 1.0

2.3 ± 1.1

2.8 ± .52

2.4 ± .47

2.6 ± .66

2.5 ± .29

2.9 ± 1.1

Lymphocytes

1.7 ± .51

1.9 ± .84

1.7 ± .62

1.8 ± .87

1.6 ± .69

2.0 ± .39

1.6 ± .39

1.8 ± .50

1.7 ± .44

1.8 ± .44

Monocytes

.45 ± .12

.39 ± .12

.44 ± .12

.36 ± .07

.37 ± .14

.43 ± .14*

.38 ± .04*

.39 ± .13*

.40 ± .09*

.44 ± .12*

Eosinophils

.12 ± .06

.13 ± .08

.11 ± .05

.12 ± .06

.12 ± .06

.14 ± .08

.14 ± .09

.16 ± .10

.16 ± .09

.16 ± .07

Basophils

.06 ± .02

.05 ± .01

.05 ± .01

.05 ± .01

.05 ± .02

.07 ± .02*

.06 ± .02*

.07 ± .02*

.07 ± .01*

.06 ± .01*

  1. * Denotes significant main effects for groups (p < 0.05) indicating that the 600 mg group had higher baselines values that persisted throughout the study, and was apparently independent of 6-OXO supplementation.